Citadel Advisors
NRXP icon

Citadel Advisors’s NRX Pharmaceuticals NRXP Stock Holding History

Citadel Advisors’s Portfolio NRXP Stock Details NRXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$917K Buy
224,200
+199,500
+808% +$659K ﹤0.01% 8413
2026
Q1 		$52.6K Sell
24,700
-11,100
-31% -$22.4K ﹤0.01% 12386
2025
Q4 		$97K Buy
35,800
+2,900
+9% +$7.78K ﹤0.01% 11667
2025
Q3 		$109K Buy
+32,900
New +$94.2K ﹤0.01% 11791
2025
Q1 		– Sell
-19,600
Closed -$43.1K – 15250
2024
Q4 		$43.1K Sell
19,600
-15,700
-44% -$21.1K ﹤0.01% 12545
2024
Q3 		$59.7K Buy
35,300
+12,890
+58% +$26K ﹤0.01% 11713
2024
Q2 		$54.7K Buy
22,410
+19,320
+625% +$68.7K ﹤0.01% 11657
2024
Q1 		$14.6K Sell
3,090
-5,710
-65% -$26.3K ﹤0.01% 13232
2023
Q4 		$40.5K Sell
8,800
-560
-6% -$1.85K ﹤0.01% 11999
2023
Q3 		$24.3K Buy
9,360
+590
+7% +$1.96K ﹤0.01% 12462
2023
Q2 		$42.4K Sell
8,770
-60
-0.7% -$361 ﹤0.01% 12003
2023
Q1 		$58.2K Sell
8,830
-7,690
-47% -$77.9K ﹤0.01% 11963
2022
Q4 		$183K Sell
16,520
-3,080
-16% -$31K ﹤0.01% 10284
2022
Q3 		$145K Sell
19,600
-2,670
-12% -$18K ﹤0.01% 10741
2022
Q2 		$134K Sell
22,270
-6,810
-23% -$89.5K ﹤0.01% 11099
2022
Q1 		$712K Buy
29,080
+240
+0.8% +$7.81K ﹤0.01% 8523
2021
Q4 		$1.38M Buy
28,840
+25,260
+706% +$1.82M ﹤0.01% 7084
2021
Q3 		$332K Buy
+3,580
New +$466K ﹤0.01% 10845

Other funds holding NRXP

BGI
B Group Inc Dallas, Texas $213M AUM 96.05% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Citadel Advisors's NRXP Position: Q2 2026 in Review

Citadel Advisors opened a new position in NRX Pharmaceuticals (NRXP) in Q2 2026: 680,043 shares worth $2.78M. The stake represents ﹤0.01% of the portfolio and ranks #5832 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in NRXP as recently as Q2 2025.

Citadel Advisors first reported a position in NRXP in Q3 2021 and has held it in 7 quarters since. 47 funds tracked by Wall St. Rank hold NRXP as of Q2 2026.

  • Citadel Advisors held 680,043 shares of NRX Pharmaceuticals worth $2.78M as of Q2 2026.
  • NRX Pharmaceuticals was a new Citadel Advisors position in Q2 2026.
  • NRX Pharmaceuticals made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #5832 holding.
  • Citadel Advisors first reported a position in NRX Pharmaceuticals in Q3 2021 and has held it in 7 quarters since.
  • 47 funds tracked by Wall St. Rank held NRX Pharmaceuticals as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.